SERES THERAPEUTICS INC's ticker is MCRB and the CUSIP is 81750R102. A total of 135 filers reported holding SERES THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.57 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $325,016 | -49.7% | 136,567 | +1.3% | 0.00% | -100.0% |
| Q2 2023 | $645,692 | +120590.1% | 134,800 | +42.9% | 0.00% | 0.0% |
| Q1 2023 | $535 | +6.6% | 94,302 | +5.2% | 0.00% | 0.0% |
| Q4 2022 | $502 | -99.9% | 89,613 | +1.9% | 0.00% | 0.0% |
| Q3 2022 | $564,000 | +109.7% | 87,924 | +12.1% | 0.00% | – |
| Q2 2022 | $269,000 | -54.3% | 78,465 | -5.0% | 0.00% | -100.0% |
| Q1 2022 | $588,000 | -14.7% | 82,578 | -0.2% | 0.00% | 0.0% |
| Q4 2021 | $689,000 | +21.3% | 82,746 | +1.4% | 0.00% | 0.0% |
| Q3 2021 | $568,000 | -69.8% | 81,567 | +3.4% | 0.00% | -50.0% |
| Q2 2021 | $1,881,000 | +29.4% | 78,847 | +11.7% | 0.00% | 0.0% |
| Q1 2021 | $1,454,000 | -21.5% | 70,603 | -6.6% | 0.00% | -33.3% |
| Q4 2020 | $1,853,000 | -1.1% | 75,626 | +14.3% | 0.00% | 0.0% |
| Q3 2020 | $1,874,000 | +601.9% | 66,184 | +18.0% | 0.00% | – |
| Q2 2020 | $267,000 | +62.8% | 56,102 | +22.1% | 0.00% | – |
| Q1 2020 | $164,000 | +3.8% | 45,931 | 0.0% | 0.00% | – |
| Q4 2019 | $158,000 | -7.1% | 45,931 | +8.5% | 0.00% | – |
| Q3 2019 | $170,000 | +42.9% | 42,348 | +14.9% | 0.00% | – |
| Q2 2019 | $119,000 | -35.7% | 36,848 | +37.0% | 0.00% | – |
| Q1 2019 | $185,000 | +50.4% | 26,892 | -0.9% | 0.00% | – |
| Q4 2018 | $123,000 | -10.9% | 27,136 | +48.8% | 0.00% | – |
| Q3 2018 | $138,000 | -17.9% | 18,241 | -6.8% | 0.00% | – |
| Q2 2018 | $168,000 | +22.6% | 19,566 | +4.5% | 0.00% | – |
| Q1 2018 | $137,000 | -29.4% | 18,721 | -1.9% | 0.00% | – |
| Q4 2017 | $194,000 | -46.8% | 19,086 | -16.2% | 0.00% | -100.0% |
| Q3 2017 | $365,000 | +43.7% | 22,767 | +1.3% | 0.00% | 0.0% |
| Q2 2017 | $254,000 | +14.9% | 22,472 | +14.8% | 0.00% | 0.0% |
| Q1 2017 | $221,000 | +17.6% | 19,582 | +3.0% | 0.00% | – |
| Q4 2016 | $188,000 | -2.6% | 19,018 | +20.9% | 0.00% | -100.0% |
| Q3 2016 | $193,000 | -56.9% | 15,732 | +1.9% | 0.00% | 0.0% |
| Q2 2016 | $448,000 | +103.6% | 15,432 | +86.7% | 0.00% | 0.0% |
| Q1 2016 | $220,000 | -18.8% | 8,265 | +7.0% | 0.00% | 0.0% |
| Q4 2015 | $271,000 | – | 7,725 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 23,117,045 | $110,730,646 | 4.94% |
| Lion Point Capital, LP | 691,803 | $3,313,736 | 1.50% |
| Eversept Partners, LP | 3,076,756 | $14,737,661 | 1.23% |
| Soleus Capital Management, L.P. | 2,045,983 | $9,800,259 | 1.09% |
| Knott David M Jr | 470,000 | $2,251 | 0.90% |
| GREAT POINT PARTNERS LLC | 938,067 | $4,493,341 | 0.88% |
| Simplify Asset Management Inc. | 550,626 | $2,637,499 | 0.35% |
| Delphia (USA) Inc. | 33,913 | $162,443 | 0.26% |
| Alpha DNA Investment Management LLC | 138,536 | $663,587 | 0.22% |
| Avoro Capital Advisors LLC | 2,500,000 | $11,975,000 | 0.16% |